Androgen receptor activation promotes tumor progression in canine and human triple negative breast cancer cell lines
Finally, results revealed that ailanthone acted as a potent AR antagonist, effectively blocking AR and Src expression in both canine and human cell lines, reducing significantly cell proliferation. The study concludes that AR and the tumor's hormonal environment are critical for TNBC progression and that ailanthone could be a beneficial treatment for both human and canine TNBC.
Authors
- Cristina Díaz del Arco (ORCID: https://orcid.org/0000-0002-6100-4967)
- Sara Cáceres (ORCID: https://orcid.org/0000-0001-6947-2127)
- Ángela Alonso‐Diez (ORCID: https://orcid.org/0000-0002-0296-2348)
- Juan Carlos Illera (ORCID: https://orcid.org/0000-0002-9178-3121)
- Belén Crespo (ORCID: https://orcid.org/0000-0001-5383-6184)
- María del Carmen Méndez Herrera
- Micaela De La Puente
- M. Illera
Institutions
- Universidad Complutense de Madrid (ES)
- Hospital Clínico San Carlos (ES)
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES)
- Department of Animal Health (VN)
Publication Details
- Journal
- Frontiers in Veterinary Science
- Published
- 2025-09-23
- DOI
- https://doi.org/10.3389/fvets.2025.1677830
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Instituto de Salud Carlos III